Related Experiment Video
Updated: Jul 7, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
FluBlok, a recombinant influenza vaccine
Victor C Huber1, Jonathan A McCullers
1St Jude Children's Research Hospital, Department of Infectious Disease, Memphis, TN 38105, USA.
Abstract:
Protein Sciences Corp and UMN Pharma Inc are developing FluBlok, an injectable trivalent influenza vaccine formulation composed of recombinant influenza hemagglutinin (HA) proteins that match the HA from the three influenza isolates that currently circulate in humans (H1N1, H3N2 and B), for the potential prevention of influenza virus infection. Phase III clinical trials to compare FluBlok and a licensed trivalent influenza vaccine for immunogenicity, safety and efficacy in preventing naturally occurring influenza are ongoing.
Related Concept Videos
Influenza
Vaccinations
Leaky Scanning
Vaccine Production
Viral Recombination
Cross-reactivity

